Farwell Lab

Publications

34 Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells  Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi K, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TS, Farwell MD, Herati RS, Huang AC Cancer Cell 2024, 42(9), 1582-1597

33. FDG PET/CT Imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD. Clinical Cancer Research 2024, 30(9), 1758-1767.

32. Artificial intelligence in immunotherapy PET/SPECT imaging McGale JP, Chen DL, Trebeschi S, Farwell MD, Wu AM, Cutler CS, Schwartz LH, Dercle L. European Radiology, 2024, 1-13

31. Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [¹⁸F]AlF-FAPI-74 Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, Liousia M, Lohith K, Xu K, Edwards KJ, Farwell MD, June CH, Albelda SM, Puré E, Sellmyer MA. Clinical Cancer Research 2022, 28(24), 5330-5342

30. Using CD69 PET imaging to monitor immunotherapy-induced immune activation Edwards KJ, Chang B, Babazada H,  Lohith K, Park DH, Farwell MD, Sellmyer MA, Cancer Immunology Research 2022, 10(9), 1084-1094

29. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N. Journal of Nuclear Medicine 2022, 63(5), 720-726

28. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial Narayan V, Barber-Rotenberg JS, Jung I-Y, Lacey SF, Rech, AJ Davis MM, Hwang W-T, Lal P, Carpenter EL,  Maude SL, Plesa G,Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo,L Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. Nature Medicine 2022, 28(4), 724-734

27 Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer Young AJ, Pantel AR, Viswanath V, Dominguez TL, Makvandi MM, Lee H, Li S, Schubert EK, Pryma DA, Farwell MD, Mach RH, Simpkins F, Lin LL, Mankoff DA, Doot RK. Journal of Nuclear Medicine 2022, 63(1), 44-50.

26. ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD, Chong EA, Bagg A, Ruella M, Farwell MD, Svoboda J, Sellmyer MA, Molecular Imaging and Biology, 2021, 12(23), 818-826.

25. Positron emission tomography imaging of poly–(adenosine diphosphate–ribose) polymerase 1 expression in breast cancer: a nonrandomized clinical trial. McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA. JAMA Oncology, 2020, 6(6), 921-923.

24. Breast cancer 18F-ISO-1 uptake as a marker of proliferation status. McDonald ES, Doot RK, Young AJ, Schubert EK, Tchou J, Pryma DA,Farwell MS, Nayak A, Ziober A, Feldman MD, DeMichele A, Clark AS, Shah PD, Lee H, Carlin SD, Mach RH, Mankoff DA. Journal of Nuclear Medicine, 2020, 61(5), 665-670.

23. Imaging CAR T Cell Trafficking with eDFHR as a PET Reporter Gene. Sellmyer MA, Richman SA, Lohith K, Hou C, Weng C-C, Mach RH, O’Connor RS, Milone MC, Farwell MD. Molecular Therapy, 2020, 28(1), 2-51.

22. First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. Pandit-Taskar N, Postow M, Hellmann M, Harding J, Barker C, O'Donoghue J, Ziolkowska M, Ruan S, Lyashchenko S, Tsai F, Farwell M, Mitchell T, Korn R, Le W, Lewis J, Weber W, Behera D, Wilson I, Gordon M, Wu A, Wolchok J. Journal of Nuclear Medicine, 2020, 61(4), 512-519.

21. Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold. Derakhshan JJ, Farwell MD. Nuclear medicine communications, 2019, 40(7), 727-733.

20. Tracking Engineered T Cell Therapies with an RNA-based Reporter Gene Chang B, Shang C, Lohith K, Farwell M. Journal of Nuclear Medicine 2019, 60 (supplement 1), 1605-1605.

19. Evaluation of the anti-PD-1 Flare Response in Patients with Advanced Melanoma Using FDG PET/CT Imaging and Hematologic Biomarkers Chang B, Huang A, Shang C, Palmer K, Schubert E, Xu W, Amaravadi R, Schuchter L, Mitchell T, Wherry E, Farwell MD. Journal of Nuclear Medicine 2019, 60 (supplement 1), 1270-1270.

18. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter E, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Sebro R, Farwell M, Hwang W-T, Moniak M, Gilmore J, Lledo L, Dengel K, Marshall A, Coughlin CM, June CH, Haas NB Journal of Clinical Oncology 2019, 37 (7_suppl), TPS347-TPS347.

17. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya A, Wubbenhorst B, Dorfman L, D’Andrea K, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier M, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao A, Mogg R, Xu W, Blumenschein W, Yearley JH, Linette G, Amaravadi RK, Schuchter LM, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC. Nature Medicine, 2019, 1.

16. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J. Cytotherapy, 2018, 20(12), 1415-1418.

15. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH. British journal of cancer. 2018, 119(10), 1200-1207.

14. Radiosynthesis and in vitro evaluation of [11C] Shield-1, a PET probe for imaging CAR T cells that express the iCasp9 suicide gene Lohith K, Kwon S, Padakanti P, Thanna S, Hou C, Weng C-C, Sellmyer M, Mach R, Farwell MD. Journal of Nuclear Medicine, 2018, 59, 61.

13. FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma. Ahmed HS, Pantel AR, Metz JM, Plastaras JP, Farwell MD. Clinical Nuclear Medicine. 2018, 43(5), e139-e141.

12. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL. The Journal of clinical investigation. 2018, 128(5), 2116-2126.  

11. In vivo monitoring of CAR T cells using [18F] fluoropropyl-trimethoprim Sellmyer M, Richman S, Lohith K, Hou C, Lieberman B, Mankoff D, Mach R, Milone M, Farwell M. Journal of Nuclear Medicine, 2018, 59, 1(suppl), 122.

10. Synthesis and initial characterization of [125I]-5-iodotubercidin, a radioligand for imaging adenosine kinase. Lohith K, Kwon S, Padakanti P, Lieberman B, Sandau U, Boison D, Mach R, Farwell M. Journal of Nuclear Medicine, 2017, 58, 1(suppl), 866.

9. Making molecular imaging a clinical tool for precision oncology: a review Mankoff DA, Farwell MD, Clark AS, Pryma DA. JAMA Oncology, 2017,  3(5), 695-701.

8. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI. Oncotarget. 2017, 8(15), 24213-24223.

7. Development of companion diagnostics Mankoff DA, Edmonds CE, Farwell MD, Pryma DA. Seminars in nuclear medicine, 2016, 46(1), 47-56.

6. Positron emission tomography Lameka K, Farwell MD, Ichise M. Handbook of clinical neurology. 2016, 135, 209-227.  

5. How imaging biomarkers can inform clinical trials and clinical practice in the era of targeted cancer therapy  Farwell MD, Clark AS, Mankoff DA. JAMA oncology. 2015, 1(4), 421-2.

4. How imaging can impact clinical trial design: molecular imaging as a biomarker for targeted cancer therapy. Mankoff DA, Farwell MD, Clark AS, Pryma DA, The Cancer Journal, 2015, 21(3), 218-224.

3. PET/CT imaging in cancer: current applications and future directions Farwell MD, Pryma DA, Mankoff DA. Cancer, 2014, 120(22), 3433-45.

2. Imaging P-glycoprotein function in rats using [11C]-N-desmethyl-loperamide Farwell MD, Chong DJ, Iida Y, Bae SA, Easwaramoorthy B, Ichise M. Annals of nuclear medicine, 2013, b, 27(7), 618-24.

1. PET quantification of pancreatic VMAT 2 binding using (+) and (−) enantiomers of [18 F] FP-DTBZ in baboons Harris PE, Farwell MD, Ichise M. Nuclear Medicine and Biology, 2013, 40(1), 60-4.